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Abstract: Ischemia and reperfusion injury (IRI) is a complex pathophysiological phenomenon,
inevitable in kidney transplantation and one of the most important mechanisms for non- or delayed
function immediately after transplantation. Long term, it is associated with acute rejection and
chronic graft dysfunction due to interstitial fibrosis and tubular atrophy. Recently, more insight has
been gained in the underlying molecular pathways and signalling cascades involved, which opens the
door to new therapeutic opportunities aiming to reduce IRI and improve graft survival. This review
systemically discusses the specific molecular pathways involved in the pathophysiology of IRI and
highlights new therapeutic strategies targeting these pathways.
Keywords: ischemia reperfusion injury; kidney transplantation; delayed graft function;
innate immune system; adaptive immune system; apoptosis; necrosis; hypoxic inducible factor;
endothelial dysfunction
1. Introduction
To date, 10% of the worldwide population suffers from chronic kidney disease (CKD).
The prevalence of the disease will most likely grow over the next decade due to the increase in
the elderly population and the growing incidence of diabetes and hypertension. In 2015, CKD was
ranked 12th in the global list of causes of death [1]. The population of patients needing renal replacement
therapy (RRT) worldwide was estimated to be approximately 4.902 million (95% CI 4.438–5.431 million)
in a conservative model and 9.701 million (95% CI 8.544–11.021 million) in a high estimate model,
illustrating the magnitude of the disease burden of end stage renal disease (ESRD) [2].
For patients with ESRD, transplantation is still the optimal treatment. Long-term survival with
kidney transplantation is dramatically better than dialysis and transplantation provides a sustainably
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higher quality of life. Unfortunately, there is a worldwide shortage of suitable donor organs for (kidney)
transplantation. The number of renal transplantations performed worldwide in 2018 was 75.664 [3].
Due to the persistent shortage of donor kidneys, many transplant centres have established large living
donor programmes and transplant teams are also now accepting increasing numbers of older and
higher risk organs, retrieved from deceased donors. The use of these extended criteria donors (ECD)
has affected outcomes after transplantation due to an often-suboptimal quality of the donor organ [4,5].
As we will face more complex donors in the future with a reduced viability such as unstable donation
after brain death (DBD) donors, donation after circulatory death (DCD) donors, and ECD, the challenge
in transplantation is to be able to use these donor sources, however, without compromising successful
immediate function and long-term graft survival after transplantation. It is therefore imperative that
the condition of every graft-to-be is optimised prior to or at the time of transplantation and that
additional injury is minimized in order to achieve the best possible post-transplant function and avoid
primary non function (PNF), delayed graft function (DGF), and rejection with chronic graft failure.
Ischemia and reperfusion injury (IRI) is inevitable in (kidney) transplantation and one of the
most important mechanisms for non- or delayed function immediately after transplantation [6–8].
It is accompanied by a proinflammatory response and is associated with acute rejection due to an
increased immunogenicity favouring T-cell mediated rejection as well as anti-body mediated rejection
(ABMR) [9,10]. In addition, it may result in progressive interstitial fibrosis and is associated with
chronic graft dysfunction due to interstitial fibrosis and tubular atrophy (IFTA) [11]. In the past decade
more insight has been gained in the complex molecular pathophysiology of IRI. This may open a door
to new therapeutic targets aiming to reduce IRI. The aim of this review is to systematically highlight
these molecular mechanisms and to discuss potential therapeutic strategies specifically targeting these
molecular pathways.
2. Ischemia and Reperfusion Injury
IRI consists of a complex pathophysiology involving activation of cell death programs, endothelial
dysfunction, transcriptional reprogramming and activation of the innate and adaptive immune
system [8]. Numerous pathways and signalling cascades are implicated (Figure 1) and it is while
worthy to dissect the distinct effects of ischemia and reperfusion (I/R).
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Figure 1. Schematic overview of the pathophysiological consequences of ischemia and reperfusion. 
I/R: ischemia/reperfusion; ATP: adenosine triphosphate; EndMT: endothelial to mesenchymal 
transition; ROS: reactive oxygen species; mPTP: mitochondrial permeability transition pore. 
2.1. Ischemia  
Due to a decrease in oxygen supply, cells will switch from an aerobic to an anaerobic 
metabolism, which results in a decrease in adenosine triphosphate (ATP) production and 
intracellular acidosis due to the formation of lactate. This causes destabilisation of lysosomal 
membranes with leakage of lysosomal enzymes, breakdown of the cytoskeleton and inhibition of 
membrane-bound Na+/K+ ATPase activity [12–14]. This last process gives rise to an intracellular 
accumulation of Na+ ions and water with as a consequence cellular oedema. Due to declined Ca2+ 
excretion, there is an intracellular Ca2+ accumulation, which causes activation of Ca2+ dependant 
proteases like calpains. Due to the acidosis, these calpains stay inactive during the ischemic period 
but may damage the cell after normalisation of the pH during reperfusion. The remaining ATP is 
broken down to hypoxanthine, which will accumulate in the cell, since further metabolism into 
xanthine requires oxygen [15]. In the mitochondria, the Ca2+ overload is responsible for generation 
of reactive oxygen species (ROS) [8]. This will lead to opening of the mitochondrial permeability 
transition pores (mPTP) after reperfusion. During the ischemic period, only small amounts of ROS 
are produced compared to the entire I/R due to the reduction of cytochromes, nitric oxide synthases, 
xanthine oxidase and reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 
activation [16–19]. 
2.2. Reperfusion 
During reperfusion, oxygen levels increase, and the pH normalises which is harmful for the 
previously ischemic cells. The intracellular Ca2+ level further increases, which activates the calpains 
causing injury to the cell structure and cell death [8]. Restoration of normoxemia leads to the 
Figure 1. Schematic overview of the pathophysiological consequences of ischemia and reperfusion.
I/R: ischemia/reperfusion; ATP: adenosine triphosphate; EndMT: endothelial to mesenchymal transition;
ROS: reactive oxygen species; mPTP: mitochondrial permeability transition pore.
2.1. Ischemia
Du to a decrease in oxygen supply, cells will switch from an aerobic to an anaerobic metabolism,
which results in a decrease in adenosine triphosphate (ATP) production and intracellular acidosis
due to the formation of lactate. This causes destabilisation of lysosomal membranes with leakage
of lysosomal enzymes, breakdown of the cytoskeleton and inhibition of membrane-bound Na+/K+
ATPase activity [12–14]. This last process gives rise to an intracellular accumulation of Na+ ions and
water with as a consequence cellular oedema. Due to declined Ca2+ excretion, there is an intracellular
Ca2+ accumulation, which causes activation of Ca2+ dependant proteases like calpains. Due to
the acidosis, these calpains stay inactive during the ischemic period but may damage the cell after
normalisation of the pH during reperfusion. The remaining ATP is broken down to hypoxanthine,
which will accumulate in the cell, since further metabolism into xanthine requires oxygen [15]. In the
mitochondria, the Ca2+ overload is responsible for generation of reactive oxygen species (ROS) [8].
This will lead to opening of the mitochondrial permeability transition pores (mPTP) after reperfusion.
During the ischemic eriod, only small amounts of ROS are produced co pared to the entire I/R due
to the reduction of cytochromes, nitric xide sy thas s, xanthine oxi ase and reduced nicotinamide
ad nine dinucleotide phosp at (NADPH) oxidas activation [16–19].
2.2. Reperfusion
During reperfusion, oxygen levels increase, and the pH normalises which is harmful for the
previously ischemic cells. The intracellular Ca2+ level further increases, which activates the calpains
causing injury to the cell structure and cell death [8]. Restoration of normoxemia leads to the production
of large amounts of ROS, together with reduction in t e antioxidant capacity [20]. This burst of
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ROS production was thought to be due to a generalised dysregulation of the electron transport chain
with electrons leaking out at non-specific sites [21]. Recently, however, Chouchani et al. [22] showed
that this superoxide production is generated by reverse action of complex I of the electron transport
chain driven by a pool of succinate, a metabolite of the citric acid cycle, accumulated during ischemia.
This massive amount of mitochondrially produced ROS is responsible for the activation of various
injurious pathways through carbonylation of proteins or lipid peroxidation. This may contribute
to injury of the cell membranes, the cytoskeleton and DNA and may lead to a disruption of ATP
generation and induction of mPTP [20]. Additionally, the combination of ROS, dysfunctioning of
the mitochondrial machinery and increase in mitochondrial Ca2+ load causes opening of the mPTP
and release of substances like cytochrome C, succinate and mitochondrial DNA (mtDNA), which are
able to induce cell death through apoptosis and necrosis and may act as danger/damage associated
molecular patterns (DAMPs) entailing activation of the innate and subsequently the adaptive immune
system [23–26].
Recent insights in the pathophysiological mitochondrial mechanisms and general understanding
of the pivotal role of the mitochondria in IRI has led to various strategies targeting mitochondria
with the aim to reduce IRI including limiting oxidative stress and mitochondrial ROS generation [20].
Both lipophilic cations and mitochondrial targeted proteins have been developed to deliver antioxidants
to the mitochondria [27]. Triphenylphosphonium (TTP), a lipophilic cation, is rapidly taken up by
mitochondria where it releases covalently bonded bioactive compounds. MitoQ, with its bioactive
compound ubiqinone, is the most investigated of these molecules. In the mitochondria ubiqinone
is reduced to ubiquinol, a powerful ROS scavenger. Administration of MitoQ in renal I/R models
resulted in reduced markers of oxidative stress, reduced renal injury and improved function [28–30].
Regarding the mitochondrial targeted proteins, the Szeto-Schiller (SS) proteins are the best known.
Exact mechanism of action is poorly understood but a possible explanation of action is through
interaction with cardiolipin, an important component of the inner mitochondrial membrane. SS peptides
have shown to reduce renal IRI in rodents [31], and its lead compound SS-31 (Elamipretide, Stealth
BioTherapeutics-Alexion Pharmaceuticals) is currently being investigated in humans for its efficacy
in reducing IRI post-angioplasty for renal artery stenosis. A pilot study administration of SS-31
before and during percutaneous transluminal renal angioplasty and stenting has shown to attenuate
post-procedural hypoxia, increased renal blood flow and improved kidney function [32].
Another strategy to reduce ROS generation is reduction of succinate formation by inhibition of
succinate dehydrogenase, preventing the accumulation of succinate, a driving force of reverse action
of complex I. This has been shown to be effective in various in vivo models of IRI including the heart
but has yet been unexplored in renal IRI [22,33].
3. Pathophysiological Consequences of IRI
3.1. Cell Death: Necrosis, Apoptosis, Regulated Necrosis and Autophagy
3.1.1. Necrosis
I/R leads to the activation of cell death programs. Of these programs, necrosis is the most
uncontrolled form. It is due to swelling of the cell and subsequent rupture of the cellular
membrane [34]. This will lead to an uncontrolled release of cellular fragments into the extracellular
space. These fragments act as DAMPs and are able to activate the innate and adaptive immune system,
entailing infiltration of inflammatory cells into the tissue and release of different cytokines.
3.1.2. Apoptosis
In contrast to the uncontrolled process of necrosis, apoptosis is a highly regulated and controlled
process in which activation of the caspase signalling cascade results in a self-limiting programmed
cell death. These caspases, a family of proteases, are essential in this process. There are two types of
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caspases: initiator caspases (2,8,9,10) and effector caspases (3,6,7) [35,36]. The initiator caspases are
activated by binding to a specific activator protein complex (death-inducing signalling complex (DISC),
apoptosome) [37]. The formed complexes then activate the effector caspases through proteolytic
cleavage upon which these proteolytically degenerate various intracellular proteins. Apoptosis gives
rise to apoptotic bodies, containing these intracellular protein fragments, via the process of membrane
blebbing. The apoptotic bodies will undergo phagocytosis before they can spill their content into
the extracellular space and therefore will generate a less immune stimulating impulse compared to
necrosis. Apoptosis can be initiated through the intrinsic pathway (mitochondrial dependent pathway)
in which the initiating signal comes from within the cell (e.g., damaged DNA, hypoxia, metabolic
stress) or the extrinsic pathway (cell death receptor pathway) due to signals from out of the cell (tumor
necrosis factor-α (TNF-α), first apoptosis signal (Fas)-ligand, FasL) (Figure 2) [37].
A protein family playing an important role in the regulation of apoptosis is the B-cell lymphoma 2
(BcL-2) family [38]. Members of this family can act as protectors (BcL-2, BcL-xL) inhibiting apoptosis,
sensors (BH3 only proteins, Bad, Bim, Bid) inhibiting the protectors, or effectors (Bax, Bad) initiating
apoptosis by enhancing the permeability of the mitochondrial membrane [39]. In case of intrinsic
signalling, intracellular signals of cell stress will lead to an increase in the BH3 only proteins resulting
in inhibition of the protectors and activation of the effectors. These effectors increase the permeability
of the mitochondrial membrane resulting in leakage of pro-apoptotic proteins upon which a caspase
activator complex, the apoptosome, is formed in the intracellular space [40–43]. The apoptosome
cleaves procaspase-9 to its active form of caspase-9, which in turn is able to activate the effector
caspase-3. In case of the extrinsic signalling, binding of TNF-α (TNF path) or the FasL, expressed
on cytotoxic T lymphocytes, (Fas path) to receptors of the TNF receptor (TNFR) family will lead to
the formation of a complex called the death-inducing signalling complex (DISC) [44–46]. The DISC,
amongst others, consisting of a death effector domain and three procaspase-8 or -10 molecules, cleaves
and activates the procaspases [47]. Activation of the initiator caspase-8 by both paths directly activates
other members of the caspase signalling cascade such as the effector caspase-3 but also can lead to an
increase in BH3-only proteins (Bim, Bid) and trigger the intrinsic pathway (Figure 2) [48].
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of the receptor-bound complex 1 made up of TNF receptor-associated death domain (TRADD), 
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(TRAF)-2 and cellular inhibitors of apoptosis (clAP)1/2) and the linear ubiquitin assembly complex 
(LUBAC). This complex 1 can lead to a pro-survival pathway or to apoptosis. In case of apoptosis the 
TRADD dependant complex IIa (consisting of TRADD, Fas-associated death domain protein (FADD) 
and caspase-8) or the RIPK-1 dependant complex IIb also known as the ripoptosome (consisting 
Figure 2. Extrinsic and intrinsic apoptotic pathway. The intrinsic pathway is mediated by intracellular
signals of cell stress leading to an increase in the BH3 only proteins (members of the B-cell lymphoma 2
(Bcl-2) family) resulting in an inhibit on of the prot ctors and activation of the effectors. The effectors
Bax and Bad increase the permeabi ity of the mitoch drial membrane (MOMP: mit chondrial
ou e membran pe me bilisation) resulting in l akage of apopt tic prote ns. O e of these proteins,
known as second mitochondria-deriv d activ tor of caspases (SMAC), binds to pr teins that inhibit
apoptosi (IAPs, by suppression of the caspase proteins) causing an inactivation of these I Ps. Another
protein released from the mitochondria is cytochrom c, which binds to Apoptotic protease activating
factor-1 (Apaf-1) and ATP. This compl x binds to procaspase-9 creati g a complex, the apoptosome.
The apoptosome cleaves procaspase-9 to its active form of caspase-9, which in turn is able to activate
the effector caspase-3. The extrinsic pathway is mediated through receptors of the tumor necrosis
factor (TNF) receptor (TNFR) family either via the TNF path or the Fas (first apoptosis signal) path.
In the TNF path binding of TNF-α to a trimeric complex of TNFR1 molecules induces activation
of the intracellular death domain and the formation of the receptor-bound complex 1 made up
of TNF receptor-associated death domain (TRADD), receptor-interacting protein kinase 1 (RIPK1),
two ubiquitin ligases (TNFR-associated factor (TRAF)-2 and cellular inhibitors of apoptosis (clAP)1/2)
and the linear ubiquitin assembly complex (LUBAC). This complex 1 can lead to a pro-survival pathway
or to apoptosis. In case of apoptosis the TRADD dependant complex IIa (consisting of TRADD,
Fas-associated death domain protein (FADD) and caspase-8) or the RIPK-1 dependant complex IIb
also known as the ripoptosome (consisting FADD, RIPK1, RIPK3 and caspase-8) is formed. In the
Fas path, presence of the Fas ligand (FasL, expressed on cytotoxic T lymphocytes) causes three Fas
receptors (CD95) to trimirize. This clustering and binding to the FasL initiates binding of FADD.
Three procaspase-8 or -10 molecules can then interact with the complex by their own death effector
domains. The complex formed is the death-inducing signalling complex (DISC) which cleaves and
activates procaspase-8 and 10. Activation of the initiator caspase-8 by both paths directly activates
other members of the caspase signalling cascade such as the effector caspase-3 but also can lead to an
increase in BH3-only proteins (Bim, Bid) and trigger the intrinsic pathway).
3.1.3. Regulated Necrosis
Recently, new pathways of a more regulated form of necrosis have been described. These processes
show features of apoptosis as well as necrosis. One of the best-known pathways of regulated necrosis
is via TNFR-1 and is called necroptosis [46]. In the absence of active caspase-8, phosphorylation
of receptor-interacting protein kinase 1 (RIPK1) and RIPK3 in complex IIb leads to formation of a
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complex called the necrosome. The necrosome recruits Mixed Kinase Domain-Like protein (MLKL),
which is then phosphorylated by RIPK3 [46]. MLKL activates the necrosis phenotype by entering
the bilipid membranes of organelles and the cellular membrane. This causes formation of pores in
these membranes and leads to release of cellular contents, functioning as DAMPs, into the extracellular
space [49]. As in necrosis the DAMPs are able to activate both the innate and adaptive immune system
promoting proinflammatory responses that activate rejection pathways [50,51]. A recent study in a
kidney transplant mouse model showed that RIPK3-deficient kidneys had better function and longer
rejection-free survival [52]. Therefore RIPK3-inhibiting drugs might be of interest in the reduction of IRI
in organ transplantation. Next to TNFR-1, other death receptors and toll like receptors (TLR) have also
shown to be able to induce necroptosis [46]. Other forms of regulated necrosis include mitochondrial
permeability transition (MPT)-associated death (involving opening of mPTP leading to necrosis instead
of apoptosis), ferroptosis (involving iron and gluthation metabolism), parthanatos (also known as
PARP-1 (Poly(ADP-ribose) polymerase-1) dependent cell death, involving the accumulation of PAR
(poly(ADP-ribose)) and the nuclear translocation of apoptosis-inducing factor (AIF) from mitochondria)
and pyroptosis (involving caspase-1 and -11 in mice and caspase-4 and -5 in humans) [53]. The role of
pyroptosis in IRI in the kidney, however, is unclear.
3.1.4. Autophagy
Cells can preserve their metabolic function and escape cellular death. This is due to autophagy
of damaged cell parts. There are several pathways of autophagy, namely, macro-autophagy,
micro-autophagy and chaperone-mediated autophagy—the last two are beyond the scope of this review.
Macro-autophagy (hereafter called autophagy) involves formation of autophagosomes containing
damaged cell parts or unused proteins. These double membrane autophagosomes travel through the
cytoplasm to fuse with lysosomes (autolysosome) leading to degradation of the damaged cell parts.
This process is continuously active at low basal levels, preserving cellular homeostasis, but stimulated
upon stress through various signals like nutrient deprivation, ROS formation, hypoxia, free amino
acids, etc. [54–56]. Cellular building blocks obtained from recycling of damaged cell parts by autophagy
may serve as anti-stress responses and energy source promoting cell survival.
The first step in autophagy, the initiation, is regulated by two kinases: mammalian target of
rapamycin complex 1 (mTOR, mTORC1) and adenosine monophosphate-activated protein kinase
(AMPK) [54,57,58]. Together, they regulate the activity of the Unc-51 like autophagy activating kinase
1/2 (ULK1/2) complex [59,60]. Activation of mTOR leads to the phosphorylation of this complex
and inhibition of autophagy (for instance, through the phosphatidylinositol 3-kinase (PI3K)/Protein
kinase B (AKT) or the mitogen-activated protein kinase (MAPK)/extracellular signal–regulated kinase
(Erk) 1/2 signalling pathway). On the other hand, activation of AMPK, upon intracellular AMP
increase, activates autophagy [61]. This occurs by inhibition of the mTORC1 through dissociation
of mTORC1 from ULK1/2 (indirect) or in a direct way by phosphorylation of ULK1/2 forming the
ULK1/2-complex [62,63]. Next to the ULK1/2 complex, inducible beclin-1 complex (or class III PI3K
complex) is involved in initiation of autophagy. This complex is activated by the ULK-1/2 complex and
inhibited by Bcl-2 and Bcl-XL. The ULK1/2 and class III PI3K complexes join to form the phagopore
and eventually the autophagosme which will fuse with a lysosome [64–69]. The content of this formed
autolysosome is degenerated, and the components are released to be reused to synthesise new proteins
or to function as an energy source for the cell (Figure 3) [70].
In renal IRI, autophagy is considered a doubled-edged sword. Upon I/R, it is mostly upregulated,
but both protective and harmful effects are observed, proposing a dual role for autophagy in
renal IRI [71,72]. Decuypere et al. [71] hypothesize that autophagy can switch roles depending
on the severity of the ischemic injury. The exact mechanism behind this switch is unclear but
may depend on the survival vs death properties of beclin1 and its interaction with the Bcl-2 family
proteins [71,73]. Autophagy can be considered a protective mechanism in (oxidative) stress injured
cells through restoring cellular homeostasis. Kidneys from older donors are at increased risk of DGF.
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The age-dependent decline in autophagy activity and age-dependant autophagic dysfunction may
be one of the underlying mechanisms of this phenomenon [74]. Extensive oxidative stress (amount
or duration), however, may have detrimental effects which eventually could trigger the switch to
aggravation of the injury through autophagy dependant cell death. Excessive or prolonged ROS
exposure may lead to the oxidative modification of macromolecules making them only partially
degradable by the autolysosome [75]. Furthermore, an energy dependent process of autophagy
could deprive the cell of necessary energy. In this light, excessive autophagy seen after prolonged
cold ischemia time in particular in DCD donors seems to be one of the underlying mechanisms
behind augmentation of reperfusion injury seen in these circumstances, thereby increasing the risk of
DGF [71,76]. Based on this dual role of autophagy in renal IRI and transplantation the goal would be to
restrict autophagy levels within a protective window. Upon severe ischemia (prolonged cold ischemia
time (CIT)) autophagy inhibitors most likely outweigh the activators [71]. Continuing efforts have to
be made to elucidate the mechanism of autophagic transition from protective to harmful function.
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Figure 3. Pathways of macro-autophagy. Initiation of autophagy is regulated by mTORC1 (mammalian
target of rapamycin complex 1) and AMPK (AMP-activated kinase). Together, they regulate the
activity of the ULK1/2 complex consisting of ULK1/2 (Unc-51 like autophagy activating kinase),
FIP200 (FAK family kinase interacting protein of 200 kDa) and the autophagy related proteins (ATG)
ATG13 and ATG10. Activation of mTOR leads to the phosphorylation of this complex and inhibition of
autophagy (for instance, through the phosphatidylinositol 3-kinase (PI3K)/ Protein kinase B (AKT) or
the mitogen-activated protein kinase (MAPK)/ extracellular signal–regulated kinase (Erk) 1/2 signalling
pathway) whereas activation of AMPK activates autophagy. AMPK, activated upon intracellular
AMP increase, is able to activate autophagy by inhibition of the mTORC1 through dissociation of
mTORC1 from ULK1/2 allowing ULK1/2 to be activated. AMPK, is also able to initiate autophagy in a
direct way by phosphorylation of ULK1/2 forming the ULK1/2-complex.Another complex involved in
the initiation is the autophagy inducible beclin-1 complex (or class III PI3K complex) which consists
of Vps34 (phosphatidylinositol 3-kinase), beclin-1 (a BH3 only domain protein member of the Bcl-2
family), vps15 and ATG14. This complex is activated by the ULK-1 complex and inhibited by Bcl-2
and Bcl-XL. The ULK1/2 and class III PI3K complexes join to form the phagopore and eventually the
autophagosme. This process is mediated by the ATG5-ATG12-ATG16 complex and the formation of
phosphatidylethanolamine-conjugated Light Chain (LC) 3 (LC3-II) facilitating elongation of the bilipid
membrane to form a closed autophagosme. The autophagosome fuses with a lysosome and the content
of the autolysosome is degenerated and the components are released to be reused to synthesise new
proteins or to function as an energy source for the cell. PDK-1: pyruvate dehydrogenase kinase-1.
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The different cell death programs described above are induced in response to common stimuli.
Several proteins in the autophagy and apoptosis pathway are shared resulting in an intimate crosstalk
between apoptosis and autophagy. Regulation of these proteins determines cellular fate to cell
survival or cell death. Caspase-mediated degradation of several autophagy regulation proteins
limits autophagosome formation and therefore autophagy [77–79]. Apoptosis inhibitors Bcl-2 and
Bcl-XL also inhibit autophagy by binding to Beclin-1 limiting its availability to form the classIII
PI3K complex [80,81]. Inhibition of cisplatin induced autophagy enhanced caspase-3 activation and
apoptosis in renal proximal tubular cells [82,83]. On the other hand, overexpression of ATG5 and
beclin-1 prevented cisplatinum induced caspase activation and apoptosis [84]. Additionally, there is
evidence that autophagy induction regulates necroptosis. Inhibition of autophagy has shown to
prevent necroptosis and vice versa inhibition of necroptosis is able to supress autophagy [85,86].
3.1.5. Targeting Cell Death Programs
Targeting pathways of cell death programs to reduce IRI seems very attractive, since it directly
preserves cellular function. Secondly, dead cells releasing DAMPs elicit a strong immune response
not only in the organ exposed to I/R but also in other organs of the individual, so called remote organ
injury. Therefore, interfering with this process might be immunosuppressive and organ protective.
The relative contribution of each of the cell death programs to IRI and outcome in transplantation,
however, has to be elucidated.
Nydam et al. [87] showed in a syngeneic mouse transplant model that administration of the
pan-caspase inhibitor Q-VD-OPh during graft retrieval and cold preservation resulted in decreased
caspase-3 expression and activity, reduced apoptosis in renal tubular cells and improved renal function
post-transplantation. The pro-apoptotic gene p53 is activated upon hypoxia, oxidative stress and
DNA damage and is able to induce cell cycle arrest, which enables DNA-repair proteins to repair
the sustained injury. However, in case of severe DNA damage it induces apoptosis by initiating the
intracellular pathway.
Inhibition of P53 in proximal tubular cells has been shown to decrease apoptotic cell death
and provide protection against IRI [88,89]. QPI-1002 is a synthetic small interfering ribonucleic acid
(siRNA) designed to reversibly and temporarily inhibit p53. In pre-clinical models it has been shown
that QPI undergoes rapid glomerular filtration and uptake by proximal tubular epithelial cells [89].
Administration of QPI-1002 has shown to be safe in humans. Two phase I dose escalating safety
and pharmacokinetics studies in patients undergoing major cardiovascular surgery (NCT00554359,
NCT00683553) has been executed without dose-limiting toxicities or safety issues. A phase I/II study
has been executed to evaluate QPI-1002 for the prevention of DGF in recipients of kidneys from
deceased donors (NCT00802347) in which treatment with QPI-1002 resulted in lower incidence and
severity of DGF [90]. Recently, a phase 3 randomized, double-blind, placebo-controlled study in
recipients (n = 594) of (older) DBD donor kidneys (>45 years) has been completed (NCT02610296,
ReGIFT-study). Results have not been reported yet.
Various pharmacological substances like necrostatins (RIPK1 inhibitors, necroptosis), ferrostatins
(ferroptosis), sanglifehrin A (MPT-associated death) and olaparib (parthanatos) and many others have
been developed to target specific key molecules of the different programs of regulated necrosis and
are currently tested in various animal and disease models (Figure 4) [91,92]. The question remains
how safe it will be to inhibit non-apoptocic cell death pathways in patients, since these pathways also
function as a backup system when apoptosis fails or is inhibited for instance, by caspase inhibitor
expressing viruses. Of these molecules, RIPK1 inhibitors have now entered clinical trials and their
safety is being tested in healthy volunteers [93,94].
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3.2. Endothelial Dysfunction
At a vascul r level, I/R leads to swelling f t e endothelial cell (ECs), loss of the glycocalyx
and degradation of the cytoskeleton. As a consequence, intercellular contact of endothelial cells
is lost, increasing vascular permeability and fluid loss to the interstitial space [95]. Furthermore,
the endothelium will produce vaso ctive substances like platelet-derived growth factor (PDGF) and
Endothelin-1 (ET-1), ausing vasoconstriction [96]. This vasoconstriction can be enhanced by a reduced
nitric oxide (NO) production during reperfusion due to decreased endothelial nitric oxide synthase
(eNOS) expression and increased sensitivity of the arterioles for vasoactive substances like angiotensin
II, thromboxane A2 and pro taglandin H2 [97–99]. Eventually this can lead to the so called no
reflow phenom non ch racterized by the absence of adequ te perfusion o microcirculatory level
despite reperfusion.
The regenerative capacity of ECs in peritubular capillaries is limited and injury to the
microcirculation may lead to permanent peritubular capillary rarefaction [100,101]. C ronic hypoxia in
these regions may induce transcription of fibrogenic genes like transforming growth factor-β (TGF-β)
and connective tissue growth factor (CTGF) together with an accumulation of α-smooth muscle actin
(α-SMA) [101]. In the end, this may lead to development of IFTA, a process which has mainly been
attributed to resident fibroblasts. More recently, however, the role of endothelial-to-mesenchymal
transition (EndMT) in this process has been described [102,103]. During EndMT, ECs lose their
endothelial phenotype (such as expression of specific endothelial markers like Von Willebrand factor
(VWF)) and acquire the phenotype of multipotent mesenchymal cells (MSC). These cells show an
increased expression of α-SMA, neuronal (N)-cadherin, vimentin and fibroblast-specific protein-1
and exhibit enhanced migratory potential and increased extracellular matrix production [104–106].
In a porcine I/R model Curci et al. [102] showed that 20%–30% of the total α-SMA+ cells emerging
after IRI were also CD31+ suggesting a different origin compared to resident activated fibroblasts.
Man et al. [107] showed that in kidney transplant recipients experiencing IFTA and allograft dysfunction,
progression of EndMT plays an important role. EndMT is controlled by complex signalling pathways
J. Clin. Med. 2020, 9, 253 11 of 33
and networks. In their porcine I/R model, Curci et al. [102] showed a critical role of complement in this
process. Kidneys of pigs treated with recombinant C1 inhibitor (C1-INH) showed preserved EC density,
significant reduction of α-SMA expression and limited collagen deposition 24 h after I/R compared
to untreated pigs. The ECs in the treated pigs showed preserved physiological conformation and
position tight to the basal layer of the vessels. The number of transitioning ECs was significantly lower
in the treated animals. In an additional in vitro experiment activating ECs with the anaphylatoxin
C3a, they showed that C3a induced down regulation of the expression of VWF whilst upregulating
α-SMA, by activating the Akt pathway. Activation of the ECs with C5a showed a similar response [102].
Targeting signalling pathways in EndMT in kidney transplantation could be of interest to reduce IFTA
and enhance long-term graft survival. More insight however has to be gained to the exact role of
EndMT in renal transplantation and what suitable targets to aim for. Furthermore, since EndMT gives
rise to multipotent MSC this placidity could be of interest to push these MSCs in the direction of
regeneration rather than fibrosis.
An important feature of IRI is the chemotaxis of leukocytes, endothelial adhesion and
transmigration of these cells into the interstitial compartment [108]. This process is initiated by
increased expression of P-selectin on the endothelial cells and interaction of P-selectin with P-selectin
glycoprotein 1 (PSGL-) expressed on the leukocytes. This interaction results in rolling of the leukocytes
on the endothelium. Subsequently, firm adherence of the leucocytes to the endothelium is achieved by
the interaction of the β2-integrins lymphocyte function-associated antigen 1(LFA-1) and macrophage-1
antigen (MAC-1 or complement receptor 3, CR3) on the leukocyte and the intracellular adhesion
molecule 1 (ICAM-1) on the endothelial cells. Platelet endothelial cell adhesion molecule 1 (PECAM-1)
thereafter facilitates transmigration into the interstitial space. Once activated, these leukocytes
will release several toxic substances like ROS, proteases, elastases and different cytokines in the
interstitial compartment which will result in further injury like increased vascular permeability,
oedema, thrombosis and parenchymal cell death (Figure 5) [109].
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Figure 5. Interaction of leukocytes and endothelial cells in the process of transmigration of leukocytes.
The increased expression of P-selectin on the endothelial cells upon I/R facilitates interaction with
P-selectin glycoprotein 1 (PSGL-) expressed on the leukocytes. This results in rolling of the leukocytes
on the endothelium. Subsequently, firm adherence of the leucocytes to the endothelium is achieved by
interaction of ly pho yte functio -associated antigen 1(LFA-1) and macrophage-1 antigen (MAC-1 or
complement receptor 3, CR3) on the leukocyte and the intracellular adhesion molecule 1 (ICAM-1)
on the endothelial cells. Finally, platelet endothelial cell adhesion molecule 1 (PECAM-1) facilitates
transmigration of the leukocytes into the interstitial space. Once activated, these leukocytes will
release several toxic substances like ROS, proteases, elastases and different cytokines in the interstitial
compartment resulting in further injury like increased vascular permeability, oedema, thrombosis and
parenchymal cell death.
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3.3. Innate and Adaptive Immune Response
IRI is accompanied by sterile inflammation in which the innate as well as the adaptive immune
system are involved.
3.3.1. Innate Immune Response
The innate, or non-specific, immune system is evolutionary the oldest part of the immune system.
It acts on infection or injury with a fast, short-lasting and non-specific response in which different cells
and systems are involved.
Toll-Like Receptor Signalling
In the innate immune response, the toll-like receptors (TLRs) play an important role [110].
TLRs are transmembrane proteins and members of the interleukin-1 receptor (IL-IR) superfamily.
They function as pattern recognition receptors (PRR) and are present on the cellular membrane and in
the cytosol of cells like leukocytes, endothelial cells and tubular cells [111]. The human TLR family
contains 10 members, TLR1–TLR10 [112]—of which, TLR2 and TLR4 have shown to be upregulated
in tubular epithelial cells upon ischemia [113–117]. Both are attributed an equal importance in
initiating apoptosis in a genetic knock-out renal I/R mouse model [115]. TLR activation leads to the
downstream recruitment of various adapter molecules (TNF receptor-associated factor 6 (TRAF6),
Myeloid differentiation primary-response protein 88 (MyD88), toll-interleukin 1 receptor (TIR) domain
containing adaptor protein (TIRAP), TIR-domain-containing adapter-inducing interferon-β (TRIF),
TRIF-related adaptor molecule (TRAM)) activating different kinases (IL-1 receptor-associated kinase
(IRAK)-1 (IRAK-1), IRAK-4, inhibitor of nuclear factor-κB kinase (IKK), TANK-binding Kinase-1
(TBK1)), leading to activation of transcription factors (nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-κB), IFN-regulatory factor 3 (IRF3) resulting in transcription of proinflammatory
genes and the subsequent inflammatory response [8,112].
TLR2 and TLR4 have polyvalent ligand binding activity and can be activated by exogeneous
(e.g., lipopolysaccharide, LPS) and endogenous ligands comprising DAMPs released upon I/R.
These DAMPs vary depending on type of injury and tissue involved. High-mobility group box-1
(HMGB-1), an intracellular protein involved in the organisation of DNA and the regulation of gene
transcription, is one of the DAMPs linked to the pathogenesis of IRI [118–120]. From the nucleus,
HMGB-1 can be released into the cytosol or extracellular space by passive leakage from injured cells or
through active secretion by immune cells [121,122].
In IRI in the kidney, TLR4 plays an important role. Bergler et al. [123] showed that TLR4 is
highly upregulated after renal IRI, and that high TLR4 expression is strongly correlated with graft
dysfunction in an allogenic renal transplant model in rats. Furthermore, TLR4-deficient mice are
protected against renal IRI and kidneys from donors with a TLR4-loss of function allele show less
pro inflammatory cytokines in the kidney after transplantation and a higher percentage of immediate
graft function [118,124]. Activation of TLR4 in renal IRI has various consequences on the graft.
First of all it promotes the release of different proinflammatory mediators like IL-6, IL-1β and TNF-α,
accompanied by an increased expression of macrophage inflammatory protein-2 (MIP-2) and monocyte
chemo attractant protein-1 (MCP-1) involved in the recruitment of neutrophils and macrophages [124].
Second, TLR-4 activation leads to increased expression of adhesion molecules ICAM-1, vascular cell
adhesion molecule 1 (VCAM-1) and E-selectin facilitating leukocyte migration and infiltration into the
interstitial space. TLR-4 signalling seems mandatory for this increased expression. Chen et al. [125]
showed that increased expression of adhesion molecules after renal IRI was absent in TLR4 knockout
mice in vivo and the addition of HMGB-1 to isolated endothelial cells increased adhesion molecule
expression on cells from wild-type but not from TLR4 knockout mice. Thirdly, activation of TLR4 on
circulating immune cells of the innate immune system leads to activation of these cells. Neutrophils and
macrophages are involved in an early stage after reperfusion. Neutrophils are regarded as the primary
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mediators of injury and their activation leads to ROS release, secretion of different proteases and renal
tissue injury [126]. Upon activation, macrophages release proteolytic enzymes and proinflammatory
cytokines like TNF-α, IL-1β and interferon-γ (IFN-γ) [127]. In TLR-4 knockout mice subjected to
IRI, neutrophil and macrophage infiltration was reduced [124]. Finally, the TLR4-facilitated immune
response is linked to renal fibrosis. The upregulation of TLR4 upon I/R induces a strong inflammatory
response accompanied by tubular necrosis, loss of brush border, formation of casts and tubular
dilatation [124]. Such a robust inflammation is known to potentiate interstitial fibrosis [128].
Proposed endogenous ligands for TLR-4 in renal IRI include HMGB-1, extracellular matrix
(ECM) components like biglycan, heparin sulphate and soluble hyaluronan, and heat shock proteins
(Hsps) [129–134]. Upon ligand binding, activation of TLR4 leads to downstream signalling via the
MyD88-dependent and MyD88 independent pathway (Figure 6). The MyD88-dependent pathway
in which MyD88 and TIRAP or MyD88 adapter-like (Mal) recruits and activates members of the
IRAK family is considered to be the dominant pathway [124,135]. Wang et al. [136] demonstrated
that MyD88- and TRIF-deficient mice showed a significant reduction in interstitial fibrosis reflected
by α-SMA and collagen I and II accumulation Furthermore, Administration of the MyD88 specific
inhibitor TJ-M2010-2, a small molecular compound, inhibiting the homodimerisation of MyD88, in a
renal I/R model in mice has shown to prolong the survival rate, preserve renal function and attenuate
the inflammatory responses and apoptosis in the kidney. In the long term, inhibition of the TLR/MyD88
signalling pathway with TJ-M2010-2 attenuated renal fibrosis via inhibition of TGF-β-induced epithelial
to mesenchymal transition [137]. Liu et al. [138] showed that pre-treatment with the synthetic TLR4
inhibitor eritoran (Eisai co., Ltd, Tokyo, Japan) in an renal I/R rat model resulted in reduced expression
of TNF-α, IL-1β and MCP-1, attenuated monocyte infiltration in the kidney and improved renal
outcome Altogether in view of the pivotal role of TLR4 in renal IRI, inhibition of TLR4 or upstream or
downstream mediators could be an interesting target in reducing IRI and optimising graft survival.
Next to TLR4, TLR 2 is markedly upregulated upon ischemic injury in the kidney and its
upregulation is associated with the initiation of an inflammatory response [139]. Kidneys of TLR2-/-
mice subjected to I/R showed less tubular damage compared to TLR2+/+ mice. Reduced levels of
MIP-2, MCP-1, and IL-6 and reduced levels of infiltrating leucocytes were seen [140]. The role of
TLR2 in the development or progression of renal fibrosis, however, is less clear. Leemans et al. [139]
showed that in a mouse model of obstructive nephropathy TLR2 does not play a significant role
in renal progressive injury and fibrosis. In addition to this de Groot et al. [141] showed in human
allograft biopsies that TLR2 expression 6, 12 and 24 months after transplantation is associated with
superior graft outcome in the long run Currently, the humanized immune globuline (Ig) G4 (IgG4)
monoclonal antibody against TLR2 OPN-305 (Tomaralimab, Opsona Therapeutics Ltd, Dublin, Ireland)
has entered phase 2 trials (NCT01794663) with the aim to reduce delayed graft function in recipients of
post-mortal donor kidneys. In the first part (A) of this study a single dose of 0.5 mg/kg administered
1h before reperfusion was associated with full inhibition of TLR2 and an 80% reduction of IL-6 [142].
Subsequently, this dose has been used in part B of the study, which has been completed but results
have not been reported yet.
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Figure 6. Toll-like receptor 4 signalling. Activation of toll-like receptor 4 (TLR4) by danger
associated molecular patterns (DAMPs), like high mobility group box-1 (HMGB-1), heat shock
proteins (hsp) and extracellular matrix (ECM) components, leads to downstream signalling via the
MyD88 (Myeloid differentiation primary-response protein 88) dependent and MyD88 independent
pathway. The MyD88-dep dent pathway in w ich MyD88 and TIRAP (toll-interl ukin 1 receptor
(TIR) domain containing adaptor protein) or MyD88 adapter-like (Mal) recruits and activates members
of the IL-1 receptor-associ ted kinase (IRAK) family is consider d to be the dominant pathway.
IRAK activation leads to recruitment of TRAF6 (TNF receptor-associated factor 6) and subsequently
activation of transforming growth factor beta-activated kinase 1 (TAK1). Activation of TAK1 then
leads to the activation of inhibitor of nuclear factor-κB kinase (IKK), which results in the release of
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) from its inhibitor, promoting
translocation to the nucleus. The MyD88 independent pathway is mediated by the adapter molecules
TIR-domain-containing adapter-inducing interferon-β (TRIF)/TRIF-related adaptor molecule (TRAM)
and downstream signalling leads to activation of 2 inhibitor of nuclear factor-κB kinase (IKK) homologs
IKKε and TANK-binding Kinase-1 (TBK1), which possibly form a complex together and activate
transcription factors NF-κB and IFN-regulatory factor 3 (IRF3). Fr m here, proinflammatory gene
transcription is initiated. TLR4 signalling is inhibited by Eritoran and TJ-M2010-2.
Complement Syste
The complement system is the second crucial player in the innate immune response in IRI.
The system consists of soluble proteins, regulatory proteins and membrane-bound receptors and
comprises three pathways. DAMPs released upon I/R are able to activate all three pathways via
binding to C1q (classical pathway), C3 (alternative pathway) or PRRs of the lectin pathway (LP).
Recently, the LP has been pointed out as the primary route of renal complement activation
after I/R [143]. Activation of the LP can take place through various PRRs like collectins (manose
binding lectin (MB ) and collectin-11) [144] and ficolins (ficolin 1-3) [145]. Upon binding of the
collectin–mannan-binding lectin serine protease (MASP) complex to carbohydrat -bearing ligands (for
insta ce, mannose or fructose expressed on stressed ells) the MASPs are activated to cleave complement
component (C) 4 (C4) and C2. LP activation is critically dependant on the action of MASP-2 [146,147].
In an isograft transplantation model in wild-type and MASP-2-deficient mice, Asgari et al. [147]
showed that renal function was preserved with MASP-2 deficiency After complex-ligand interaction,
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LP proceeds with cleavage of C4 and C2, mediated by MASP-2, leading to the synthesis of the
classical pathway C3 convertase. Recently, a C4 independent bypass in the LP pathway was also
demonstrated [122]. This could explain why C4-deficient mice are not protected against renal I/R and
cellular mediated rejection [148,149]. One of the PRRs assigned an important role in the LP is collectin-11
(CL-11), a soluble C-type lectin containing a carbohydrate recognition domain and MASP binding
domain [150]. In renal tissue, tubular cells are the main source of CL-11 and expression increases
after IRI [151]. CL-11 has been appointed an important role in complement activation in the kidney.
It has been shown that CL-11 engages l-fucose at sites of ischemic stress and inflammation initiating
the LP [147]. In a renal I/R model, CL-11-deficient mice showed no post-ischemic and complement
mediated injury supporting the importance of CL-11 in triggering renal complement activation.
All activating routes converge and lead to the formation of the C3 convertase (C4b2b, C3bBbP).
C3 convertase cleaves and activates additional C3, creating C3a and C3b. C3b together with C4b2b
forms the C5 convertase, which will cleave C5 into C5a and C5b. C5b together with C6–9 will then
form the Membrane Attack Complex (MAC, C5b-9). The formed complement effectors will lead to
opsonisation (C3b), chemotaxis of neutrophils and macrophages (C3a, C5a) [143]. The formed MAC
inserted into the cellular membrane is associated with a proinflammatory response via noncanonical
NF-KB signalling (Figure 7) [152,153].
Next to inducing inflammation and cell death, the complement system is able to modulate
antigen presentation and T cell priming via C3a and C5a and is therefore playing a role in donor
antigen sensitisation and rejection [154]. Antigen-presenting cells (APC) express C3 and C5 along
with complement receptors C3aR and C5aR1. Upon complement activation in the extracellular space,
C3a and C5a increase the presentation of alloantigens and expression of co-stimulatory molecules
on the APC enhancing APC priming of T cells [143]. Furthermore, C3a and C5a promote T-cell
differentiation of CD4+ and CD8+ T-cells. CD8+ cells mediate vascular and cellular T-cell mediated
rejection. Upon activation, CD4+ T-cells can stimulate further CD8+ T-cell differentiation, they can
proliferate and differentiate to memory and effector CD4+ cells which can activate macrophages, recruit
leukocytes and stimulate inflammation and finally CD4+ cells stimulate B-cell differentiation and in
the end antibody production [143]. The B-cells response can also be enhanced in a direct manner via
C3b and C3d on the APC and the complement receptor 2 (CR2) on the B-cell. Activation of the B-cell
by binding to the donor alloantigen induces class switching of the donor specific antibody from IgM to
IgG. Subsequently, ABMR occurs when IgG donor specific antibodies (DSA) recognizes antigens in the
kidney graft and engage with C1q, C1r and C1s to activate the classical pathway [143]. Under normal
physiological circumstances, formation of the complement effectors is controlled by proteins (soluble
or surface bound) that mediate break down of the C3 and C5 convertases. After I/R this balance shifts
to uncontrolled complement activation predisposing the graft to complement mediated injury and
rejection [155].
Many interventions on the level of C3, C5, and regulatory proteins in I/R injury and especially
kidney transplantation have been evaluated in pre- and clinical studies [156]. Eculizumab (Soliris®,
Alexion Pharmaceuticals, New Haven, CT, USA) is to date the best studied complement inhibitor
in kidney transplantation. Therapeutic inhibition of C5 with the use of eculizumab, an anti-human
C5 micro antibody, showed potential in the prevention and/or treatment in AMBR [157–159] and
has been investigated as such in several phase 2/3 clinical trials (NCT01567085, NCT01106027,
NCT01399593). All studies report a safety profile of the drug that is consistent with that reported
for eculizumab’s approved indications like atypical haemolytic uremic syndrome. Results of these
trials suggest a potential role of eculizumab in the prevention and treatment of ABMR in patients
with DSA [160,161]. Next to ABMR, eculizumab has been investigated for the prevention of DGF
(NCT01919346, NCT02145182). Again, the safety profile was good but pre-treatment with eculizumab
had no effect on the incidence of DGF. Groups in these studies, however, were rather small [162].
Another anti-C5 antibody Tesidolumab (LFG-316, MorphoSys, Novartis) has currently entered phase 1
studies (NCT02878616).
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In addition to targeting terminal complement pathways, therapeutics targeting complement
initiation (C1) and amplification (C3, convertases) have been developed. C1 esterase inhibitors (C1-INH)
should not be considered complement-specific inhibitors, since these broad protease inhibitors and
their functions extend beyond the classical pathway and even beyond the complement system [163].
The C1INH Cinryze®(Shire US Inc., Lexington, MA, USA) is recently being evaluated for treatment
of ABMR (NCT02547220). The study was terminated May 2019 following a pre-scheduled interim
analysis, it was determined that the study met the pre-specified criteria for futility. Cinryze®is
still listed to be tested as a pre-treatment to reduce IRI and DGF (NCT02435732). Another C1INH,
Berinert®(CSL Behring, King of Prussia, PA, USA), has been evaluated in a phase 1/2, double-blind,
placebo-controlled study assessing its safety and efficacy for prevention of delayed graft function
in recipients of deceased donor kidneys [164]. Although the primary outcome measure (DGF) was
not met, treatment with Berinert®was associated with significantly fewer dialysis sessions 2 to
4 weeks post-transplantation. In addition, a better renal function was seen at 1 year compared with
the placebo treated group. No significant adverse events were noted in this study [164]. Finally,
Mirococept (APT070) a membrane-localising C3 convertase inhibitor is currently being evaluated in
a double-blind randomised controlled investigation its efficacy for preventing IRI deceased donor
kidneys (EMPIRIKAL-trial, ISRCTN49958194) [165].
Translation to the Adaptive Immune System
The link between the innate and adaptive immune response is made by dendritic cells (DCs,
Figure 8). DCs are APCs and play an essential role in the pathogenesis of IRI. Immature DCs can
be activated by DAMPs via TLRs and the complement system. After maturation, they are able to
activate the adaptive immune system in a direct manner by antigen presentation to B- and T-cells or
indirectly via cytokine signalling [8,166]. This process can already start in the donor in which in case of
a DBD donor, DCs are activated by oxidative stress or C5a and present donor antigens to T-cells of the
recipient [167]. Furthermore, it is thought that DCs (subtype CDC11c+ and F4/80+) play an important
role in the early pathophysiology of IRI by secretion of TNF-α, Chemokine (C-C motif) ligand 5
(CCL5), IL-6 and MCP-1within the first 24h after IRI [168]. Further, at a later stage, DCs contribute
to allograft dysfunction. Batal et al. [169] looked at kidney transplant biopsies performed > 15 days
after transplantation and found that a high DC density was independently associated with poor
graft survival. Additionally, they found that high DC density was correlated with an increased T-cell
proliferation and poor patient outcome in patients with high total inflammation scores of biopsies,
including inflammation in areas of tubular atrophy. In these patients, DC density could predict allograft
loss. When looking at the origin of the DCs they showed that initially donor DC predominated but
found that in late biopsies the majority of DCs were of recipient origin. These data suggest a potential
rationale to target DCs influx in the kidney to improve long-term allograft survival.
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3.3.2. Adaptive Immune Response
In contrast to the non-specific nature of the innate immune response, the role of the adaptive
immune system is to recognize alloantigens and to react with an alloantigen-specific response,
simultaneously generating immunological memory. Involved cells are B- and T-cells.
T-Cells
Activation of T-cells occurs through binding of the T-cell receptor (TCR) on the surface of the
T-cell, to the major histocompatibility complex (MHC, in case of humans the human leucocyte antigen
(HLA) system) on the APC. This can be in a direct way when the TCR binds to unprocessed allogenic
MHC on the APC of the donor or in an indirect manner when MHC proteins of the donor have been
taken up by APC of the recipient, processed and presented by the MHC of the recipient [170]. In case
of IRI, CD4+ T helper (Th) cells as well as CD8+ cytotoxic T-cells are found in the kidney and are
important mediators of IRI [171–174]. T-cell-deficient mice showed attenuated renal IRI and adoptive
T-cell transfer experiments in athymic mice resulted in acute kidney injury (AKI) [175–177].
The TCR on CD4+ T-cells can only bind to MHC class 2 molecules (HLA DP, DQ, DR).
Upon activation, these CD4+ T-cells become cytokine producing effector cells harming the graft
through cytokine mediated inflammation [170]. The effector CD4+ Th cells can differentiate into three
major subtypes Type 1 (Th1), Type 2 (Th2) and Th17 cells depending on the cytokines they produce
and the transcription factors they express. This differentiation process, referred to as polarisation,
starts with induction in lymphoid tissue. Cytokines produced by APCs (DCs and macrophages),
NK cells, basophils and mast cells act on T-cells stimulated by the antigen and co-stimulators.
This induces transcription of cytokine genes characteristic for the particular subset. Upon continued
activation, genetic modifications occur, keeping the characteristic cytokine genes in a transcriptionally
active state (commitment). The cytokines produced by the subset promote development of this subset
and inhibit differentiation toward other subsets (amplification) [170]. The main effector cytokine of Th1
cells is IFN-γ and the key Th1 transcription factors are signal transducer and activator of transcription
(STAT) 4 (STAT-4) and the T-box transcription factor T-bet. Main effector cells are macrophages, B-cells,
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CD8+ T-cells and CD4+ T-cells (amplification). IFN-γ secreted by Th1 cells will activate macrophages
leading to secretion of inflammatory cytokines (TNF, IL-1 and IL-2), an increased production of toxic
substances like ROS, NO and lysosomal enzymes and finally stimulation of expression of costimulatory
molecules enhancing the efficiency of the macrophage as APC [170]. The main effector cytokines
of Th2 are IL-4, IL-5 and IL-13 and key transcription factors are GATA binding protein 3 (GATA-3)
and STAT-6. IL-4 act on B-cells to stimulate production of IgE antibodies which can lead to mast cell
degranulation upon binding of IgE with mast cells. IL-5 activates eosinophils, inducing defence against
helminthic infections. IL-4 and IL-13 are involved in alternative macrophage activation promoting
development of M2 macrophages which have anti-inflammatory effects and may promote tissue
repair and fibrosis [170]. Signature cytokines of Th17 are IL-17 and IL-22. Differentiation into this
subtype is mediated by IL-6 and TGF-β leading to activation of transcription factors STAT-3 and
retinoic acid-related orphan receptor γt (RORγt) respectively. IL-17 act on leukocytes and tissue
cells and stimulates production of several chemokines and cytokines (TNF-α, IL-1β, IL-6) that recruit
neutrophils and to a lesser extend monocytes to generate an inflammatory response. IL-22 produced in
epithelial cells is primarily involved in maintaining the barrier function of epithelia [170]. Th17 T-cell
most likely play a significant role in IRI-induced inflammation. STAT-3 KO mice are protected from
renal IRI via downregulation of Th17 activity [178]. The differentiated T-cells can convert from
one subtype to another by changes in activation circumstances [179]. It is suggested that Th1/Th2
ratio plays an important role in the pathogenesis of IRI [180,181]. Yokota et al. [181] demonstrated
that STAT-6-deficient mice with a defective Th2 phenotype have enhanced renal I/R injury whereas
STAT-4-deficient mice have mild improved function In addition, Loverre et al. [182] showed that
kidney transplant recipients experiencing DGF predominantly expressed Th1 phenotype within the
graft In literature both Th1 and Th17 cells are associated with T-cell mediated rejection [183–188].
The TCR on CD8+ T-cells can only bind to MHC class 1 molecules (HLA A, B, C) presented on
APCs. Upon activation in lymphoid tissue, they differentiate into cytotoxic T-cells (CTLs) or memory
cells. This differentiation is facilitated by CD4+ Th1 cells by secreting cytokines that act directly on the
CD8+ cells [170]. The main cytokines involved are IL-2 (proliferation, differentiation CTL/memory
cell), IL-12/IFN (differentiation CTL), IL-15 (memory cell survival), IL-21 (memory cell induction).
The CTLs are able to kill cells which present the allogenic class 1 MHC of the donor in the graft.
This through binding on the target cell and release of granule content into the immune synapse.
These granules contain perforin and granzymes. Perforin induces the uptake of granzymes into the
target cell. These granzymes are capable of activating caspases and inducing apoptosis. The killing of
the target cell can also be Fas/Fas-L mediated in which the CTL expose the Fas ligand on the membrane
which will bind to the Fas receptor on the target cell inducing apoptosis. Only CTLs that are activated
in the direct way (by donor MHC on donor APC) are able to kill graft cells [170]. Like CD4+ Th cells,
CTL secrete inflammatory cytokines, (predominantly IFN-γ) that attribute to inflammation and injury
of the graft. The role of CD8+ cells in early phase of renal IRI is unclear, in a mouse model CD4+
deficient mouse was protected from IRI but CD8+ deficient mouse was not [176].
Ko et al. [189] showed that already 6 h after renal IRI, transcriptional activity occurs in T-cells
and that these gene expression changes persist up to 4 weeks after the event. Genes involved in
immune cell trafficking and cellular movement were most upregulated in the early phase (6 h, 3 days).
On day 10 this was shifted to genes related to cellular development products involved in immune
responses and on day 28 to genes involved in cellular and humoral immune response involved in
antigen presentation. In addition, they found that the CC motif chemokine receptor 5 (CCR5) was one
of the most upregulated genes at all time points, which was confirmed at a protein level. Subsequently,
the addition of CCR5 antibody attenuated IRI and led to decreased T-cell activation [189].
B-Cells
Next to alloreactive CD4+ and CD8+ T-cells, antibodies (immune globulins, Ig) against the graft
contribute to rejection. Most of these Igs are produced by Th dependant alloreactive B-cells. The naive
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B-cell recognizes allogenic MHC-molecules, processes these MHC-molecules and presents them to
Th cells that were activated previously by the same alloantigen presented by APCs. The produced
Igs (IgM/IgG) are then able to induce complement activation, and activation of neutrophils, NK cells
and macrophages. The T-cells are responsible for T-cell mediated rejection and B-cells together with
complement activation for ABMR [170].
Regulatory T-Cells
The T-cells which most likely play a protective role in renal IRI are regulatory T-cells (Tregs),
a subset of CD4+ T-cells whose function is to supress the innate as well as the adaptive immune
response and maintain self-tolerance. Tregs can be discriminated from other T-cells by expression of
FoxP3 amongst other proteins like CD25. FoxP3 is probably the most important transcription factor for
Treg differentiation. The mechanism of action of Tregs is production of immune suppressive cytokines
IL-10 and TGF-β, reduction of APC is to stimulate T-cells (possibly by binding to B7 proteins on the
APC) and finally consumption of IL-2, an important growth factor for other T-cells [170]. TGF-β inhibits
various immune cells amongst which: proliferation and effector functions of T-cells, macrophages,
neutrophils and endothelial cells. It regulates differentiation of FoxP3+ Tregs and promotes polarisation
towards Th17 cells. Furthermore, TGF-β promotes tissue repair by the ability to stimulate collagen
synthesis and matrix modifying enzyme by macrophages and fibroblasts. IL-10 inhibits the production
of IL-12 by activated macrophages and DCs, therefore inhibiting these cells and their IFN-γ production.
It also inhibits T-cell activation by inhibiting the expression of co-stimulators and MHC-II molecules
on DCs and macrophages [170].
Tregs play a potentially promising role in the reduction of IRI and graft tolerance [190–193].
Currently, several clinical trials are running evaluating the safety and effeciacy of FoxP3 cellular therapy
in kidney transplantation (NCT02091232, NCT03284242, NCT01446484) [194,195]. However, all that
glitters is not gold, since recent studies have shown that human FoxP3+ T-cells show great variations
in gene expression phenotype and function [196–199]. Furthermore, recently a subset of FoxP3+ Tregs
mimicking Th cells was discovered that secreted pro-inflammatory cytokines [200]. Also, the effect of
different immune suppressive agents on the Treg phenotype needs to be elucidated, since these drugs
might influence Treg phenotype [200,201]. Altogether, more insight in function and biology is needed
before this therapy finds its way to clinical settings.
3.4. Transcriptional Reprogramming
Finally, cells can protect themselves from hypoxia and ischemia and maintain homeostasis via
an evolutionary conserved mechanism with the use of oxygen sensors and activation of specific
transcription factors. These so called hypoxic inducible factors (HIFs) regulate various genes involved
in the metabolic cell cycle, angiogenesis, erythropoiesis, energy conservation and cell survival and are
therefore able to induce a protective cell response to hypoxia [202].
HIFs are heterodimeric transcription factors consisting of an α and β subunit. There are two types
of α subunits, HIF-1α and HIF-2α, which have common, but also subunit-specific target genes. In the
kidney, HIF-1α is predominantly localized in tubular and glomerular cells, whereas HIF- 2α can be found
in glomerular cells, peritubular endothelial cells and fibroblasts [203–205]. In aerobic circumstances,
HIFs are inactive. Oxygen-sensing prolylhydroxylase (PHD) hydroxylates the amino acid proline
on the HIF-1α/HIF-2α subunit. This induces a conformational change enabling von Hippel–Lindau
tumour suppressor protein (pVHL) to bind with the α-subunit, leading to degradation of the HIF-α
subunit. Ischemia/hypoxia will lead to inhibition of the oxygen-dependent PHD, which enables nuclear
translocation of the α subunit, binding of the α and β subunit and formation of HIF. In the nucleus HIF
binds with the hypoxia response promotor element (HRE) leading to the transcription of various genes
like glycolysis enzymes Glut-1 and aldolase (enabling ATP production under hypoxic circumstances),
NF-κB, TLRs, adenosine receptors, vascular endothelial growth factor (VGEF), CD73 and erythropoietin.
Activation of HIF can also occur in normoxemic circumstances, for instance, by ROS, LPS, various
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cytokines and TCR-CD28 stimulation. Transcriptional reprogramming is a consequence of I/R that
should be considered a protective mechanism (Figure 9) [206].
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Figure 9. Intracellular stabilisation and activation of hypoxic inducible factor. Under normoxemic
conditions, proline on the hypoxic inducible factor (HIF) α (HIFα) subunit is rapidly hydroxylated
by oxygen-sensing prolyl hydroxylase (PHD). This induces a conformational change enabling von
Hippel–Lindau tumour suppressor protein (pVHL) to bind with the α-subunit, leading to degradation
of the HIF-α subunit. Ischemia (or other signals like lipopolysaccharide (LPS), various cytokines, etc.)
will lead to inhibition of the oxygen-dependent PHD, enabling nuclear translocation of the α subunit,
binding of the α and β subunit and formation of HIF. In the nucleus, HIF binds with the hypoxia
response promotor element (HRE) leading to the transcription of various genes. VGEF: vascular
endothelial growth factor.
Conde et al. [207] showed in various models and human post-transplantation biopsies that
HIF-1α is induced in a biphasic manner namely during the hypoxic as well as the reperfusion phase.
They pointed out the PI3K/Akt mTOR pathway to be responsible for this HIF-1α accumulation during
the normoxemic reperfusion phase. In their study, this second increase (e.g., during reperfusion)
seemed crucial for tubular cell survival and recovery. During the hypoxic phase, an increase in HIF-1
resulted predominantly in the upregulation of PHD3 and VGEF mRNA, which remained elevated
during oxygenation. EPO mRNA was upregulated upon reperfusion. EPO and VGEF have been
suggested to be involved in proximal tubular regeneration [208–210]. Their human post-transplantation
biopsies revealed HIF-1α expression in proximal tubular cells without ischemic damage or features
of regeneration suggesting a protective role for HIF-1α during I/R [207]. Oda et al. [211] had similar
findings in patients receiving a DBD/DCD donor kidney. Their analysis of 46 post-transplant biopsies,
gained 1h after reperfusion, showed that expression levels of PI3K, Akt, mTOR and HIF-1α were
significantly higher in patients without DGF compared to patients experiencing DGF (76% of the
patients). The expression levels of HIF-1α and donor type (DCD) were independently associated
with DGF HIF-2α expression in renal endothelial cells is suggested in several studies to be protective
against renal IRI via protection and preservation of the vasculature endothelium by upregulation
of angiogenic factors like VGEF and their receptors Tie2 and VGEFreceptor-2 (FLK-1) [212–215].
Increased production of HIF in myeloid and lymphoid cells influences the innate and adaptive immune
response. T-cell activation and proliferation is reduced under hypoxic conditions [216]. A study of
Zhang et al. [217] revealed a hypoxia/HIF-2α/adenosine2A receptor axis to be responsible in reduction
of NK T-cells activation and renal IRI upon I/R. HIF-1α induces a shift from Th1 to Th2 cells (decrease
J. Clin. Med. 2020, 9, 253 22 of 33
Th1/Th2 ratio) accompanied by a decrease in excretion of inflammatory cytokines. Furthermore,
HIF-1α promotes transcription of FoxP3 and therefore generation activation of Tregs.
Various PHD inhibitors have been developed and tested in animal I/R models. In a rat model,
Wang et al. [218] showed that use of the PHD-1 inhibitor acetate prior to the ischemic event was
able to stabilize HIF in a dose-dependent manner and was associated with improved renal outcome.
In addition, in an allogenic renal transplant model in rats, the use of the PHD inhibitor FD-4497
pre-donation was associated with increased HIF expression and improved graft outcome and reduced
mortality of recipients [219]. Hence, activation and/or upregulation of HIF could be an interesting
approach to reduce renal IRI and improve renal transplant outcome. Several PHD inhibitors are
currently being tested in clinical trials in order to treat anaemia in patients with chronic kidney disease
but have not been tested in the field of transplantation yet.
4. Summary
The past decade’s research in kidney transplant recipients has focussed on post-transplant patient
management, with a predominant emphasis on immunosuppression. However, the biggest ‘hit’ to the
donor organ is encountered during the process of donation and reperfusion at time of transplantation,
i.e., ischemia and reperfusion injury. An important initiating step in IRI is the uncontrolled ROS
formation during reperfusion and dysfunction of the mitochondrial machinery leading to the opening
of mPTP and the release of DAMPs in the intra- and extracellular space. From here, several injury
cascades are activated, including activation of cell death programs like apoptosis and (regulated)
necrosis, endothelial dysfunction implicating increased vasoconstriction upon reperfusion, loss of
specific phenotype of endothelial cells and transmigration of leucocytes into the interstitial space.
Activation of the innate and subsequently the adaptive immune system will take place through binding
of DAMPs to the toll-like receptors and activation of the complement system, leading to further injury
of the graft, increased immunogenicity favouring T-cell and antibody mediated rejection and the
initiation of fibrosis associated with chronic graft dysfunction. Currently, several novel agents targeting
various pathways are tested and, although most are still in the preclinical phase, some have already
entered clinical trials. Intervention early in this cascade of events (e.g., on a mitochondrial level),
seems very attractive, since mitochondrial dysfunction plays a pivotal role in the initiation of IRI.
Due to the complexity of the pathophysiological mechanisms, however, it may be predicted that a
multiple treatment strategy using a combination of agents given at various time points during the
donation, preservation and transplantation process will most likely be the best strategy to reduce IRI.
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